Latest News-Harbour Biomed Mediaroom_Page

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

CAMBRIDGE, Mass., May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company pro...

2024-05-23 07:23 2491

Harbour BioMed Reports Full Year 2023 Financial Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour ...

2024-03-28 22:10 4884

Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development

CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM ...

2024-02-27 09:23 2717

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 23, 2024 /PRNewswire/ -- Harbour B...

2024-01-24 12:40 2715

Harbour BioMed Announces Positive Profit Alert

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 18, 2024 /PRNewswire/ -- Harbour B...

2024-01-19 12:52 6518

Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

* Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, w...

2023-12-15 07:30 2737

Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery

CAMBRIDGE, Mass., Dec. 10, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology in...

2023-12-11 09:00 2103

Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics

CAMBRIDGE, Mass., Dec. 3, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology inn...

2023-12-04 13:19 1833

Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates

CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology in...

2023-11-13 16:04 1953

Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement

CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology in...

2023-10-13 23:26 3454

Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene

CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM...

2023-09-14 16:00 2016

Harbour BioMed Announces 2023 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour B...

2023-08-28 17:08 3425

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour B...

2023-08-28 16:30 2192

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2023 /PRNewswire/ -- Harbour Bi...

2023-08-08 16:10 3514

Nona Biosciences Announces Business Update of Collaboration on Antibody Drug Conjugate (ADC) with DualityBio

CAMBRIDGE, Mass., July 13, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM ...

2023-07-14 08:29 2381

Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 13, 2023 /PRNewswire/ -- Harbour B...

2023-07-13 18:11 5046

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 29, 2023 /PRNewswire/ -- Harbour B...

2023-06-29 21:26 3353

Nona Biosciences Appoints Steve Arkinstall, D. Phil., as Chief Scientific Advisor

CAMBRIDGE, Mass., June 6, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM H...

2023-06-07 09:00 3428

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

* HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinica...

2023-06-05 09:01 2970

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

* Porustobart in combination of toripalimab showed promising anti-tumor activity * Porustobart ...

2023-05-29 09:42 3011